Skip to content
10-Q

Quarterly Report

BridgeBio Oncology Therapeutics, Inc. BBOT

0001193125-26-219829

← back to feed
Filed
May 12, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 7, 2026 80.11M sh
Shares Diluted Q1 2026 · Mar 31, 2026 80.03K sh
Shares Diluted Q1 2026 · Mar 31, 2025 406.72K sh
Capex Q1 2026 · Mar 31, 2026 $24K
Capex Q1 2026 · Mar 31, 2025 $162K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$35.92M
Operating Cash Flow restated Q1 2026 · Mar 31, 2025 −$19.6M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $52.66M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $373.69M
Stockholders Equity Q1 2026 · Mar 31, 2026 $372.28M
Stockholders Equity Q1 2026 · Dec 31, 2025 $411.1M
Stockholders Equity restated Q1 2026 · Mar 31, 2025 −$200.03M
Stockholders Equity restated Q1 2026 · Dec 31, 2024 −$178.64M
Current Liabilities Q1 2026 · Mar 31, 2026 $43.26M
Current Liabilities Q1 2026 · Dec 31, 2025 $35.04M
Total Liabilities Q1 2026 · Mar 31, 2026 $45.37M
Total Liabilities Q1 2026 · Dec 31, 2025 $37.29M
Current Assets Q1 2026 · Mar 31, 2026 $266.5M
Current Assets Q1 2026 · Dec 31, 2025 $432.4M
Total Assets Q1 2026 · Mar 31, 2026 $417.65M
Total Assets Q1 2026 · Dec 31, 2025 $448.38M
Eps Diluted Q1 2026 · Mar 31, 2026 −$526.11
Eps Diluted Q1 2026 · Mar 31, 2025 −$54.23
Eps Basic Q1 2026 · Mar 31, 2026 −$526.11
Eps Basic Q1 2026 · Mar 31, 2025 −$54.23
Sga Expense Q1 2026 · Mar 31, 2026 $6.38M
Sga Expense restated Q1 2026 · Mar 31, 2025 $2.5M
Rd Expense Q1 2026 · Mar 31, 2026 $39.8M
Rd Expense Q1 2026 · Mar 31, 2025 $20.64M
Net Income Q1 2026 · Mar 31, 2026 −$42.11M
Net Income restated Q1 2026 · Mar 31, 2025 −$22.06M
Operating Income Q1 2026 · Mar 31, 2026 −$46.18M
Operating Income restated Q1 2026 · Mar 31, 2025 −$23.14M